MMIRF
Price
$0.05
Change
-$0.00 (-0.00%)
Updated
Dec 16 closing price
SAGE
Price
$5.04
Change
-$0.23 (-4.36%)
Updated
Dec 18, 04:59 PM (EDT)
63 days until earnings call
Ad is loading...

MMIRF vs SAGE

Header iconMMIRF vs SAGE Comparison
Open Charts MMIRF vs SAGEBanner chart's image
Medmira
Price$0.05
Change-$0.00 (-0.00%)
Volume$73.75K
CapitalizationN/A
Sage Therapeutics
Price$5.04
Change-$0.23 (-4.36%)
Volume$15.9K
CapitalizationN/A
MMIRF vs SAGE Comparison Chart
Loading...
MMIRF
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
SAGE
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
View a ticker or compare two or three
VS
MMIRF vs. SAGE commentary
Dec 18, 2024

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is MMIRF is a Sell and SAGE is a Hold.

COMPARISON
Comparison
Dec 18, 2024
Stock price -- (MMIRF: $0.05 vs. SAGE: $5.27)
Brand notoriety: MMIRF and SAGE are both not notable
Both companies represent the Biotechnology industry
Current volume relative to the 65-day Moving Average: MMIRF: 283% vs. SAGE: 135%
Market capitalization -- MMIRF: $41.9M vs. SAGE: $322.38M
MMIRF [@Biotechnology] is valued at $41.9M. SAGE’s [@Biotechnology] market capitalization is $322.38M. The market cap for tickers in the [@Biotechnology] industry ranges from $486.73B to $0. The average market capitalization across the [@Biotechnology] industry is $2.67B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

MMIRF’s FA Score shows that 1 FA rating(s) are green whileSAGE’s FA Score has 1 green FA rating(s).

  • MMIRF’s FA Score: 1 green, 4 red.
  • SAGE’s FA Score: 1 green, 4 red.
According to our system of comparison, MMIRF is a better buy in the long-term than SAGE.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

MMIRF’s TA Score shows that 3 TA indicator(s) are bullish while SAGE’s TA Score has 4 bullish TA indicator(s).

  • MMIRF’s TA Score: 3 bullish, 3 bearish.
  • SAGE’s TA Score: 4 bullish, 4 bearish.
According to our system of comparison, both MMIRF and SAGE are a good buy in the short-term.

Price Growth

MMIRF (@Biotechnology) experienced а -0.73% price change this week, while SAGE (@Biotechnology) price change was -5.39% for the same time period.

The average weekly price growth across all stocks in the @Biotechnology industry was -3.65%. For the same industry, the average monthly price growth was +1.43%, and the average quarterly price growth was +4.23%.

Reported Earning Dates

SAGE is expected to report earnings on Feb 19, 2025.

Industries' Descriptions

@Biotechnology (-3.65% weekly)

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
SAGE($322M) has a higher market cap than MMIRF($41.9M). MMIRF YTD gains are higher at: -18.386 vs. SAGE (-75.681). MMIRF has higher annual earnings (EBITDA): -1.75M vs. SAGE (-371.15M). SAGE has more cash in the bank: 569M vs. MMIRF (2.91M). MMIRF has less debt than SAGE: MMIRF (8.85M) vs SAGE (10.3M). SAGE has higher revenues than MMIRF: SAGE (106M) vs MMIRF (383K).
MMIRFSAGEMMIRF / SAGE
Capitalization41.9M322M13%
EBITDA-1.75M-371.15M0%
Gain YTD-18.386-75.68124%
P/E RatioN/AN/A-
Revenue383K106M0%
Total Cash2.91M569M1%
Total Debt8.85M10.3M86%
FUNDAMENTALS RATINGS
MMIRF vs SAGE: Fundamental Ratings
MMIRF
SAGE
OUTLOOK RATING
1..100
8861
VALUATION
overvalued / fair valued / undervalued
1..100
4
Undervalued
25
Undervalued
PROFIT vs RISK RATING
1..100
85100
SMR RATING
1..100
10097
PRICE GROWTH RATING
1..100
3565
P/E GROWTH RATING
1..100
10097
SEASONALITY SCORE
1..100
50n/a

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

MMIRF's Valuation (4) in the null industry is in the same range as SAGE (25) in the Pharmaceuticals Other industry. This means that MMIRF’s stock grew similarly to SAGE’s over the last 12 months.

MMIRF's Profit vs Risk Rating (85) in the null industry is in the same range as SAGE (100) in the Pharmaceuticals Other industry. This means that MMIRF’s stock grew similarly to SAGE’s over the last 12 months.

SAGE's SMR Rating (97) in the Pharmaceuticals Other industry is in the same range as MMIRF (100) in the null industry. This means that SAGE’s stock grew similarly to MMIRF’s over the last 12 months.

MMIRF's Price Growth Rating (35) in the null industry is in the same range as SAGE (65) in the Pharmaceuticals Other industry. This means that MMIRF’s stock grew similarly to SAGE’s over the last 12 months.

SAGE's P/E Growth Rating (97) in the Pharmaceuticals Other industry is in the same range as MMIRF (100) in the null industry. This means that SAGE’s stock grew similarly to MMIRF’s over the last 12 months.

TECHNICAL ANALYSIS
Technical Analysis
MMIRFSAGE
RSI
ODDS (%)
Bullish Trend 2 days ago
68%
Bullish Trend 2 days ago
59%
Stochastic
ODDS (%)
Bullish Trend 3 days ago
66%
Bearish Trend 2 days ago
79%
Momentum
ODDS (%)
Bearish Trend 2 days ago
79%
Bearish Trend 2 days ago
79%
MACD
ODDS (%)
Bearish Trend 2 days ago
75%
Bullish Trend 2 days ago
77%
TrendWeek
ODDS (%)
Bearish Trend 2 days ago
74%
Bearish Trend 2 days ago
81%
TrendMonth
ODDS (%)
Bearish Trend 2 days ago
69%
Bearish Trend 2 days ago
85%
Advances
ODDS (%)
N/A
Bullish Trend 8 days ago
76%
Declines
ODDS (%)
N/A
Bearish Trend 2 days ago
81%
BollingerBands
ODDS (%)
Bullish Trend 2 days ago
67%
Bullish Trend 2 days ago
71%
Aroon
ODDS (%)
N/A
Bearish Trend 2 days ago
83%
View a ticker or compare two or three
Ad is loading...
MMIRF
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
SAGE
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
ETFs / NAMEPrice $Chg $Chg %
VRIG25.190.01
+0.04%
Invesco Variable Rate Investment Grd ETF
LQD108.870.01
+0.01%
iShares iBoxx $ Invmt Grade Corp Bd ETF
HYTR21.88-0.01
-0.05%
Counterpoint High Yield Trend ETF
XBAP34.19-0.03
-0.09%
Innovator US Eq Acltd 9 Bfr ETFTM April
SVXY52.21-0.62
-1.17%
ProShares Short VIX Short-Term Futures

MMIRF and

Correlation & Price change

A.I.dvisor tells us that MMIRF and NWPHF have been poorly correlated (+30% of the time) for the last year. This A.I.-generated data suggests there is low statistical probability that MMIRF and NWPHF's prices will move in lockstep.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To MMIRF
1D Price
Change %
MMIRF100%
N/A
NWPHF - MMIRF
30%
Poorly correlated
N/A
TECX - MMIRF
29%
Poorly correlated
+6.76%
AZTR - MMIRF
24%
Poorly correlated
-2.71%
SRPT - MMIRF
22%
Poorly correlated
-0.81%
SAGE - MMIRF
22%
Poorly correlated
-1.40%
More